Plain-English translation of NCT06264180 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a combination of two medications — (VO) plus — can help people with advanced melanoma whose cancer has stopped responding to previous immune therapies. About 400 patients will be randomly assigned to receive either this new combination or one of several standard treatment options chosen by their doctor. The goal is to see if this new approach can help people live longer and control their cancer better.
Advanced melanoma is a serious form of skin cancer, and while immune therapies have helped many patients, some people's cancers stop responding to these treatments. This medication is designed to work in a different way to help patients whose tumors have become resistant to standard immune drugs.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new medication combination or a standard treatment chosen by your doctor. You will need to visit the clinic regularly for blood tests, imaging scans to measure your tumor, and physical exams to monitor how the treatment is working and check for side effects. The trial will continue until your cancer progresses, you experience severe side effects, or the study ends.
AI-generated summary from trial data · Jul 17, 2026 · Not medical advice
United States